A PRe-pOsT Interventional Study Evaluating Gardasil Nine-valent Human Papilloma Virus (HPV) Vaccine Humoral and Cellular Immune Responses in People With or Without HIV
Latest Information Update: 07 Aug 2026
At a glance
- Drugs Human Papillomavirus 9-valent recombinant vaccine Merck (Primary)
- Indications Human papillomavirus infections
- Focus Pharmacodynamics
- Acronyms PROTECT
Most Recent Events
- 04 May 2025 Status changed from not yet recruiting to recruiting.
- 07 Mar 2025 Planned number of patients changed from 180 to 120.
- 07 Mar 2025 Planned initiation date changed from 1 Feb 2025 to 1 Mar 2025.